Artiva Biotherapeutics, Inc. Overview
Pro stress-test →Artiva Biotherapeutics is a clinical-stage biotechnology company developing off-the-shelf, allogeneic natural killer (NK) cell therapies for autoimmune diseases and cancers. The company's lead candidate, AlloNK®, is a non-genetically modified, cryopreserved NK cell therapy being evaluated in combination with monoclonal antibodies, addressing large patient populations in refractory rheumatoid arthritis and B-cell driven malignancies.
Strategic Profile
Pro stress-test →Artiva differentiates itself through scalable, off-the-shelf cell therapy manufacturing with no specialized oncology infrastructure requirements, enabling community-based administration. The company combines established manufacturing technology (licensed from GC Cell) with multiple clinical programs addressing both autoimmune diseases and hematologic/solid tumors through a dual-trial strategy.
Competitive Landscape
Pro stress-test →Artiva competes in the emerging NK cell therapy space with companies developing CAR-T and CAR-NK approaches. Direct competitors include Nkarta Therapeutics, Glycostem Therapeutics, and others in cell immunotherapy. Artiva's off-the-shelf approach competes against autologous CAR-T therapies by offering scalability, reduced manufacturing complexity, and broader accessibility without requiring personalized manufacturing timelines.
Industry Context
Artiva Biotherapeutics, Inc. operates in Cell Therapy / Immunotherapy - Biotechnology.
Key facts
Founded: 2019 · Headquarters: San Diego, California · Market cap: $67.7M